Emmanuel Macron delivered another impassioned speech at the Parisian university on Thursday. Europe could die if it fails to implement key security and economic policy decisions, he warned.
The Oxford-AstraZeneca COVID-19 vaccine is fast becoming a subject of notoriety. First, will States obtain it? Second, will they use it? The first answer has generally been affirmative, given the vaccine s ease of storage and relative cheapness. The second is becoming increasingly difficult.
Orders have been made and supplies – some of them anyway - furnished, but vials and batches are not being used. Countries are either restricting or suspending the jab. AstraZeneca finds itself mounting what can only be a round-the-clock communications battle trying to dissuade officials not to put the brakes on.
Various artillery pieces have been marshalled against it. In late January, French President Emmanuel Macron expressed disappointment with the vaccine a mere few hours before the European Medicines Agency (EMA) approved its use on all adults. The real problem on AstraZeneca is that it doesn t work the way we were expecting it to, he told press members. We re waiting for the EMA resu
March 13, 2021 at 3:20 pm
Back when Moderna and Pfizer were doing their stage 3 trials on the vaccine and had to report adverse effects in the trial participants to the US Food and Drug Administration, it was reported that the FDA took some time to conclude that a woman participant who was struck by lightning did not suffer an adverse effect from the vaccine.
And over the next 6 months or so 10,000+ Americans who have been given the vaccine will die of cancer, heart attacks or strokes: correlation is not causation!
The health authorities in various countries are simply making things worse (in terms of reassuring the public) by suspending inoculations because of a few cases of blood clots. Covid was giving some people blood clotting problems right from the beginning
The Oxford-AstraZeneca COVID-19 vaccine is fast becoming a subject of notoriety. First, will States obtain it? Second, will they use it? The first answer has generally been affirmative, given the vaccine’s ease of storage and relative cheapness. The .
German paper doubles down on Oxford vaccine claims spectator.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from spectator.co.uk Daily Mail and Mail on Sunday newspapers.